Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 11, 2024, titled "Alembic Pharmaceuticals receives USFDA Final Approval for Diltiazem HydrochlorideExtended-Release Capsules USP, 120 mg, 180 mg, 240 mg, 300 mg, and 360 mg".